Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;98(3):e14084.
doi: 10.1097/MD.0000000000014084.

Risk factors for bone metastasis in patients with primary lung cancer: A systematic review

Yujie Niu  1   2   3 , Yiting Lin  1 , Hailin Pang  1 , Weiwei Shen  1 , Lili Liu  1 , Helong Zhang  1   4
Affiliations

Risk factors for bone metastasis in patients with primary lung cancer: A systematic review

Yujie Niu et al. Medicine (Baltimore). 2019 Jan.

Abstract

Background: Bone metastases (BM) are prevalent among lung cancer (LC) patients. Although some studies revealed associated factors for BM, each of these papers focused on a few factors. Few studies have identified the potential risk factors through a systematic review.

Methods: We searched through PubMed, MEDLINE, Web of Science, EMBASE, Cochrane Library and Cochrane Central Registerof Controlled Trials for literature from January 1990 to November 2017. The types of literature included case-control studies, cohort studies, randomized controlled trials and systematic reviews.

Results: From included 12 studies, we identified that lower blood calcium, T4 stage, N3 stage, P-stage III, nonsquamous, bone sialoprotein expression, elevated carcino-embryonic antigen levels were risk factors for bone metastasis in lung cancer patients.

Conclusion: We identified that T4 stage, N3 stage, and positive bone sialoprotein expression associated with an increased risk of bone metastasis. Further studies are needed to assess these relationships and to establish the risk prediction model of bone metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The systematic review was registered with the PROSPERO International Prospective Register of Systematic Review (http://www.crd.york.ac.uk/prospero) (registration number: CRD42013003744) and reported using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines in the peer-reviewed literature.

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of the selection of studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655–64. - PubMed
    1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165–76. - PubMed
    1. Al Husaini H, Wheatley-Price P, Clemons M, et al. Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 2009;4:251–9. - PubMed
    1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s–9s. - PubMed
    1. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390–6. - PubMed

Publication types